Inside Innovation

A new analysis argues that Seattle is uniquely positioned to lead the next decade of artificial intelligence development due to its infrastructure, talent, and cross-industry

AGC Biologics is advancing modular single-use bioreactor systems that enable a scale-out manufacturing approach to expand production capacity while maintaining consistent conditions. Instead of increasing

A new study co-led by the Institute for Systems Biology (ISB) shows that a rare form of lung cancer can change identity as it grows,

A new study presents a computational modeling system that enables scientists to predict how cells behave and change over time using an intuitive, language-based framework.

University of Washington biochemist and Nobel Prize winner David Baker said he remains committed to staying in Seattle so he can focus on the work

Omeros reported stronger-than-expected fourth quarter results, driven primarily by its partnership with Novo Nordisk for rare disease therapy zaltenibart. The company posted $86.5 million in

Immusoft received a $15 million grant from the California Institute for Regenerative Medicine to support clinical development of its engineered B cell therapy, ISP-001, for

The Health Sciences and Services Authority (HSSA) of Spokane awarded $3.25 million in grants to five bioscience and health companies to support research, development, and

Researchers from the Tapscott lab identified KHDC1L as a circulating biomarker for DUX4 activity in facioscapulohumeral muscular dystrophy. Facioscapulohumeral muscular dystrophy is driven by abnormal

Seattle’s life sciences market remains stable despite declines in federal and venture funding, according to Colliers’ 2026 outlook report. The report highlights continued leasing activity

Nobel Laureate David Baker is leading a new University of Washington initiative backed by $7 million to develop designer enzymes and proteins for applications in

Just – Evotec Biologics has been awarded a multi-year contract by BARDA to optimize the biomanufacturing of monoclonal antibodies targeting filovirus diseases including Ebola and